These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 8445052)

  • 1. Tumoricidal effect of human PBMC following stimulation with OK-432 and its application for locoregional immunotherapy in head and neck cancer patients.
    Kubota E; Katano M; Kurokawa H; Imamura H; Katsuki T; Yamamoto H; Hisatsugu T; Nagumo F; Tadano J
    J Craniomaxillofac Surg; 1993 Jan; 21(1):30-7. PubMed ID: 8445052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytokine-inducing activity and antitumor effect of a liposome-incorporated interferon-gamma-inducing molecule derived from OK-432, a streptococcal preparation.
    Okamoto M; Gohda H; Ohe G; Yoshida H; Matsuno T; Saito M; Sato M
    J Immunother; 2000 Jan; 23(1):94-103. PubMed ID: 10687142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The antitumor effects of locally injecting human peripheral blood mononuclear cells treated with OK-432 into the tumor site: the possible role of a tumor growth inhibitory factor (TGIF).
    Katano M; Mizoguchi T; Yamamoto H; Nakamura M; Matsuo T; Hisatugu T; Kisu T; Yamaoka K; Tokunaga O
    Jpn J Surg; 1990 Jan; 20(1):76-82. PubMed ID: 2304290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interferon gamma enhances lymphokine-activated killer cell adhesion but not lysis of head and neck squamous cell carcinoma.
    Scher RL; Carras A; Schwab D; Richtsmeier WJ; Koch WM
    Arch Otolaryngol Head Neck Surg; 1995 Nov; 121(11):1271-5. PubMed ID: 7576474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of tumor growth inhibitory factor (TGIF) in human mononuclear cells by OK-432, a streptococcal preparation.
    Katano M; Yamamoto H; Mizoguchi T; Hisatsugu T
    Cancer Immunol Immunother; 1988; 27(3):198-204. PubMed ID: 3141056
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A possible clinical application of multicytokine-producing cytotoxic mononuclear cell (MCCM) therapy.
    Katano M; Kubota E; Yamamoto H; Nakamura M; Matsuo T; Hisatsugu T; Katsuki T; Koga H; Ikezaki K; Tabuchi K
    Biotherapy; 1991; 3(4):373-9. PubMed ID: 1786201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Augmentation of cytotoxicity of lymphokine activated killer cells on ovarian tumor cells by various biological response modifiers.
    Nio Y; Zighelboim J; Berek JS; Bonavida B
    Anticancer Res; 1990; 10(2A):441-6. PubMed ID: 2346317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of OK-432 on the proliferation and cytotoxicity of lymphokine-activated killer (LAK) cells.
    Yamamoto K; Tanaka R; Yoshida S; Ono K; Mori H; Taniguchi Y; Oda T; Watanabe T
    J Immunother; 1999 Jan; 22(1):33-40. PubMed ID: 9924697
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effect of lymphokine-activated killer cells of head and neck tumors in vitro and in nude mice].
    Duan DS
    Zhonghua Er Bi Yan Hou Ke Za Zhi; 1993; 28(5):281-3, 314. PubMed ID: 8192930
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Locoregional immunotherapy of head and neck cancers utilizing allogeneic spleen cells--a report of 2 cases.
    Kubota E; Katano M; Imamura H; Kurokawa H; Katsuki T; Yamamoto H; Hisatsugu T; Nagumo F; Tadano J
    Biotherapy; 1993; 6(3):175-82. PubMed ID: 8292459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of cytokines in the adoptive immunotherapy of an experimental model of human head and neck cancer by human IL-2-activated natural killer cells.
    Rabinowich H; Vitolo D; Altarac S; Herberman RB; Whiteside TL
    J Immunol; 1992 Jul; 149(1):340-9. PubMed ID: 1535088
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Local adoptive immunotherapy of human head and neck cancer xenografts in nude mice with lymphokine-activated killer cells and interleukin 2.
    Sacchi M; Snyderman CH; Heo DS; Johnson JT; d'Amico F; Herberman RB; Whiteside TL
    Cancer Res; 1990 May; 50(10):3113-8. PubMed ID: 2334906
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effect of malignant ascitic fluids and OK-432 on the induction of LAK activity in peripheral blood mononuclear cells of gynecological cancer patients].
    Kanaoka Y; Umesaki N
    Nihon Sanka Fujinka Gakkai Zasshi; 1991 Jun; 43(6):611-8. PubMed ID: 1856521
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin 2 and lymphokine-activated killer cells.
    Gemlo BT; Palladino MA; Jaffe HS; Espevik TP; Rayner AA
    Cancer Res; 1988 Oct; 48(20):5864-7. PubMed ID: 3139285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effective in vivo induction of lymphokine-activated killer (LAK) cells by pretreatment with a streptococcal preparation, OK-432.
    Shimoda K; Saito T; Kobayashi M; Nomoto K
    Biotherapy; 1992; 5(1):63-9. PubMed ID: 1389903
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The possible use of spleen cells for the adoptive immunotherapy of cancer patients.
    Katano M; Yamamoto H; Kubota E; Nakamura M; Matsuo T; Nagumo F; Hisatsugu T; Katsuki T; Tadano J
    Surg Today; 1993; 23(1):13-20. PubMed ID: 8461601
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Augmentation of the lymphokine-activated killer cell response in head and neck cancer patients by combination interleukin-2 and interferon-alpha.
    Wanebo H; Blackinton D; Weigel T; Turk P; Mehta S
    Am J Surg; 1991 Oct; 162(4):384-7. PubMed ID: 1951894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Adoptive immunotherapy by intra-arterial infusion of ATLAK or Allo-TLAK cells in patients with head and neck cancer].
    Ikawa T; Eura M; Fukiage T; Murakami H; Yamasaki S; Fukuda K; Fukushima M; Arishima S; Maehara T; Ishikawa T
    Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-2):1438-47. PubMed ID: 2786378
    [TBL] [Abstract][Full Text] [Related]  

  • 19. OK-432 develops CTL and LAK activity in mononuclear cells from regional lymph nodes of lung cancer patients.
    Takahashi K; Harauchi D; Kimura S; Saito S; Monden Y
    Int J Immunopharmacol; 1998 Aug; 20(8):375-88. PubMed ID: 9778099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytotoxicity of interleukin 2-induced lymphokine-activated killer (LAK) cells against human leukemia and augmentation of killing by interferons and tumor necrosis factor.
    Teichmann JV; Ludwig WD; Thiel E
    Leuk Res; 1992; 16(3):287-98. PubMed ID: 1560676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.